IFNA1 and systemic lupus erythematosus: Ronnblom et al. showed that SLE was developed in 1 out of 135 patients with malignant carcinoid tumors treated with IFNα of an extremely high dose daily of 3~6 × 106 U, 3 times a week [78], which means that substantially higher IFNα was required for SLE to develop, and that even under a higher dose of IFNα, only a few individuals succumb from SLE.